StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX - Free Report) in a research note issued to investors on Thursday. The firm issued a hold rating on the stock.
Brooklyn ImmunoTherapeutics Stock Down 13.0 %
NYSE BTX traded down $0.14 during trading hours on Thursday, hitting $0.94. 56,736 shares of the company were exchanged, compared to its average volume of 515,543. The firm has a market cap of $55.30 million, a price-to-earnings ratio of -0.41 and a beta of 4.61. The company has a 50 day moving average of $1.21 and a two-hundred day moving average of $1.63. Brooklyn ImmunoTherapeutics has a 52-week low of $0.17 and a 52-week high of $10.10.
About Brooklyn ImmunoTherapeutics
(
Get Free Report)
Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.
Featured Articles
Before you consider Brooklyn ImmunoTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brooklyn ImmunoTherapeutics wasn't on the list.
While Brooklyn ImmunoTherapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
